weekend biotech lab 6th - 7th july 2013, page-8

Purple....

"Of the rest of the Aussie biotech field, I am abyssmally ignorant, and yet there's a few pearlers out there that put AHZ in the shade."

Perhaps of SP performance of late (ISN) immediately comes to mind although I don't think it's possible that there are any junior biotechs out there whose prospects would put AHZ into the shade.... (and at AHZ's MC, just over $50 million!)

On one hand....

- A revolutionary soft tissue patch, already being used by 5 of Australia's leading heart surgeons for babies despite having yet to receive TGA approval, which overcomes all of the deficiencies inherent in currently available soft tissue patch technology. Numerous competitive advantages both in use for surgeons and in patient outcomes....

And on the other...

- An HSV-2 Phase I trial for a vaccine developed by the legendary Professor Ian Frazer about to kick off utilising revolutionary technology which has had amazing results in pre-clinical trials.....

I don't know if it gets better than that. If anyone can think of a company which puts AHZ's prospects in the shade I'd love to hear it.